SCHEMBL1448708

SCHEMBL1448708

COC(=O)c1c([N+](=O)[O-])ccc(F)c1CC(N=C=O)OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
RECQL P46063 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
SIRT6 Q8N6T7 1/20 0.33
AR P10275 1/20 0.33
PELP1 Q8IZL8 1/20 0.33
ABL1 P00519 1/20 0.33
BCR P11274 1/20 0.33
WDR5 P61964 1/20 0.33
ALDH1A1 P00352 3/20 0.33
PDGFRB P09619 1/20 0.33
FGFR1 P11362 1/20 0.33
PDGFRA P16234 1/20 0.33
FLT1 P17948 1/20 0.33
FGFR3 P22607 1/20 0.33
KDR P35968 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 2/20 0.32
CNR2 P34972 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1448706 0.78 ABL1 (0.35) LMNATDP1ABL1BCRALDH1A1
SCHEMBL1448819 0.77 ABL1 (0.39) LMNARECQLTDP1SIRT6ABL1
SCHEMBL1448737 0.76 KMT2A (0.37) LMNARECQLTDP1SIRT6ABL1
SCHEMBL1448297 0.74 FBP1 (0.43) LMNAALDH1A1KMT2A
SCHEMBL1448192 0.74 TDP1 (0.40) LMNATDP1SIRT6ABL1BCR
SCHEMBL1449060 0.74 CYP4A11 (0.40) LMNARECQLTDP1SIRT6ABL1
SCHEMBL30395006 0.72 SMN1; SMN2 (0.42) LMNATDP1SIRT6WDR5ALDH1A1
SCHEMBL1448702 0.72 SMN1; SMN2 (0.35) LMNATDP1ABL1BCRALDH1A1
SCHEMBL1448325 0.71 KMT2A (0.44) LMNARECQLTDP1SIRT6ALDH1A1
SCHEMBL1448986 0.70 SMN1; SMN2 (0.41) LMNATDP1SIRT6ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1784399-B1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2011-06-15 EP disclosed
US-7910585-B2 Pyrimidine derivatives NOVARTIS AG (CH) 2011-03-22 US disclosed
US-20080293708-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1784399-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP disclosed
WO-2006021457-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293708-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS LMNA 3279/4885RECQL 157/4885TDP1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.